Key result
Higher predicted heart age in cancer patients links to ~3% higher mortality per year.
Why the study?
Cancer survivors face an elevated risk of cardiovascular disease, and predicted heart age offers a simplified method to communicate cardiovascular risk. However, predicted heart age in cancer populations and its distribution across different cancer types were unknown.
Do predicted heart age (PHA) and excess heart age (EHA) differ by cancer status and predict all-cause and cardiovascular mortality in US adults aged 30–74 years without prevalent cardiovascular disease?
Cohort (n=13,771)
Yes
Do predicted heart age (PHA) and excess heart age (EHA) differ by cancer status and predict all-cause and cardiovascular mortality in US adults aged 30–74 years without prevalent cardiovascular disease?
Although predicted heart age and excess heart age are significantly elevated in cancer survivors—especially those with lung, bladder, and prostate cancers—they offer limited incremental prognostic value for mortality over chronological age due to competing mortality risks and omission of cancer-specific treatment factors.
Answers are grounded in this paper and cite their sources.
Predicted heart age may aid risk communication in cancer survivors without outperforming chronological age for mortality prediction; leaves open whether excess heart age guides cardio-oncology management.
Introduction Cardiovascular disease (CVD) and cancer are leading causes of death, with cancer survivors facing an elevated risk of CVD. Predicted heart age (PHA) offers a simplified method to communicate cardiovascular risk. PHA in cancer populations and its distribution amongst different cancer types is unknown. This study aimed to investigate the relationship between PHA, excess heart age (EHA), and cancer status in a nationally representative cohort. Methods and results Data from 13 771 NHANES participants (2009–2018), representing 122 772 557 US adults, were analysed. Survey-weighted multivariable regression models assessed associations of PHA and EHA by cancer status. Cox proportional hazards and Fine–Gray models evaluated all-cause and CVD mortality, respectively. Kaplan–Meier survival curves were stratified by cancer status. Individuals with cancer had significantly higher PHA (66.14 vs. 54.56 years) and EHA (8.05 vs. 5.84 years) compared with individuals without cancer. Heart age metrics varied by cancer type, with the largest increases in PHA observed for lung, bladder, and prostate cancers. Chronological age was the most robust predictor of mortality, particularly when modelled continuously (adjusted HR for all-cause mortality 1.07 [1.03–1.10] in cancer; 1.07 [1.05–1.08] in non-cancer). PHA showed similar categorical discrimination, while EHA provided little incremental prognostic value after adjustment for sociodemographic variables. Conclusion Heart age metrics may help highlight cardiovascular vulnerability in populations with cancer, but their prognostic value is limited by competing mortality and omission of cancer-specific risks. Future refinement through inclusion of treatment exposures, inflammatory and cardiac biomarkers, and non-fatal cardiovascular outcomes may improve cardiovascular risk prediction in this population.
No takes yet. Share an insight, caveat, or question.
Rees et al. (2026) conducted a cohort in Cancer and cardiovascular disease risk (n=13,771). Predicted heart age (PHA) and history of cancer vs. Individuals without a history of cancer was evaluated on All-cause mortality (continuous Predicted Heart Age in individuals with cancer, adjusted model) (HR 1.03, 95% CI 1.01-1.04, p=0.001). Individuals with cancer had higher predicted heart age than non-cancer controls, though chronological age best predicted mortality.
Synapse has enriched 10 related papers. Consider them for comparative context: